Myomo (NYSEAMERICAN:MYO – Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $11.51 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.
Myomo (NYSEAMERICAN:MYO – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $11.70 million for the quarter, compared to the consensus estimate of $10.35 million. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%. On average, analysts expect Myomo to post ($0.32) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.
Myomo Stock Up 1.7%
Myomo stock opened at $1.21 on Friday. The company has a debt-to-equity ratio of 1.98, a current ratio of 2.31 and a quick ratio of 2.01. Myomo has a fifty-two week low of $0.60 and a fifty-two week high of $1.89. The firm has a fifty day moving average price of $1.38 and a two-hundred day moving average price of $1.09. The firm has a market cap of $47.93 million, a price-to-earnings ratio of -3.56 and a beta of 1.74.
Insider Activity at Myomo
About Myomo
Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.
The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.
Featured Stories
- Five stocks we like better than Myomo
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
